Cargando…

Normocomplementaemic urticarial vasculitis: effective treatment with omalizumab

We report two patients with normocomplementaemic urticarial vasculitis with impressive response to omalizumab. This contrasts recent reports on hypocomplementaemic urticarial vasculitis syndrome, highlighting the need for clinical trials of omalizumab in normocomplementaemic urticarial vasculitis.

Detalles Bibliográficos
Autores principales: de Brito, Marianne, Huebner, Gisela, Murrell, DedeeF, Bullpitt, Peter, Hartmann, Karin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6149008/
https://www.ncbi.nlm.nih.gov/pubmed/30258566
http://dx.doi.org/10.1186/s13601-018-0222-y
Descripción
Sumario:We report two patients with normocomplementaemic urticarial vasculitis with impressive response to omalizumab. This contrasts recent reports on hypocomplementaemic urticarial vasculitis syndrome, highlighting the need for clinical trials of omalizumab in normocomplementaemic urticarial vasculitis.